Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Mus musculus

ABSTRACT: Effect of systemic exposure of JAK1 Inhibition (AZ13748709) in C3H/HeJ Mice with Alopecia Areata In Vivo

PROVIDER: PRJNA369114 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR5210950_1.fastq.gz	Fastqsanger.gz
	SRR5210950_2.fastq.gz	Fastqsanger.gz
	SRR5210960_1.fastq.gz	Fastqsanger.gz
	SRR5210960_2.fastq.gz	Fastqsanger.gz
	SRR5210970_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 48

Similar Datasets

Treatment of C3H/HeJ grafted mice with baricitinib [topical]

Project description:The C3H/HeJ grafted model of alopecia areata was used to determine the efficacy of systemic baricitinib at preventing alopecia or treating established disease. The efficacy of topical baricitinib at treating established alopecia in the C3H/HeJ grafted model was also assessed. Microarrays were performed on skin RNA at week 0 and week 12 after starting treatment in all models.

2015-05-01 | GSE61554 | GEO

Treatment of C3H/HeJ grafted mice with baricitinib [systemic]

2015-05-01 | GSE61552 | GEO

Treatment of C3H/HeJ grafted mice with baricitinib [prevention]

2015-05-01 | GSE61551 | GEO

Treatment of C3H/HeJ grafted mice with baricitinib [prevention]

2015-05-01 | E-GEOD-61551 | biostudies-arrayexpress

Treatment of C3H/HeJ grafted mice with baricitinib [systemic]

2015-05-01 | E-GEOD-61552 | biostudies-arrayexpress

Treatment of C3H/HeJ grafted mice with baricitinib [topical]

2015-05-01 | E-GEOD-61554 | biostudies-arrayexpress

Effect of systemic exposure of JAK1 Inhibition (AZ13748709) in C3H/HeJ Mice with Alopecia Areata In Vivo

Project description:JAK inhibition by means of clinically available pan JAK inhibitors has recently demonstrated great efficacy in both restoring hair growth and resolving inflammation in the skin of patients with Alopecia Areata (AA). These effects are dose dependent and mainly efficacious at ranges close to a questionable risk profile. Given the great responses to JAK inhibition and the current lack of efficacious treatments in AA, it is exciting to explore the possibilities to separate the beneficial and adverse effects in order to provide a successful treatment option for these patients where the medical need is still vastly unmet. We have demonstrated that specific inhibition of JAK1 at relevant concentrations produces a fast resolution of inflammation and complete restoration of hair growth in the C3H/HeJ model of AA and importantly, that systemic exposure is essential for efficacy.

2023-01-30 | GSE94236 | GEO

JAK inhibition in human CD8+ T-cells and C3H/HeJ Mice with Alopecia Areata In Vivo

Project description:JAK inhibition in human CD8+ T-cells and C3H/HeJ Mice with Alopecia Areata In Vivo

| PRJNA369110 | ENA

Mus musculus

Project description:miRNA profiling of C3H/HeJ mice with and without spontaneous alopecia areata

| PRJNA369613 | ENA

Selective Janus kinase 1 inhibition resolves inflammation and restores hair growth offering a viable treatment option for alopecia areata

Project description:JAK inhibition by means of clinically available pan JAK inhibitors has recently demonstrated great efficacy in both restoring hair growth and resolving inflammation in the skin of patients with Alopecia Areata (AA). These effects are dose dependent and mainly efficacious at ranges close to a questionable risk profile. Given the great responses to JAK inhibition and the current lack of efficacious treatments in AA, it is exciting to explore the possibilities to separate the beneficial and adverse effects in order to provide a successful treatment option for these patients where the medical need is still vastly unmet. Selective JAK1 inhibition mainly affects genes downstream of STAT1, STAT3 & STAT6 in human immune cells. Importantly, pathways like T-cell differentiation and lymphopoiesis are less affected by the selective JAK1 inhibitor versus less specific JAK inhibitors like tofacitinib and ruxolitinib. These findings indicate that it is feasible to develop more selective and specific JAK1 inhibitors that are as efficacious as pan-JAK inhibitors but with a better safety profile as systemic exposure is mandatory for efficacy in this disease.

2023-01-30 | GSE94235 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data